Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
468-02-010 ISMRM Abstract

The decrease of CMRO2 was associated with depression severity in Parkinson’s disease with type-2 diabetes mellitus

Primary: Neuro - Parkinson's Disease
Secondary: Contrast Mechanisms - Arterial Spin Labelling
468-02-010 · Type 2 Diabetes · Tuesday, 12 May, 9:15 AM–10:10 AM · Digital Posters Row I
Keywords: Parkinson's Disease Depression Arterial spin labeling Type 2 diabetes mellitus Quantitative Susceptibility Mapping (QSM)
Accepted
Zeng Wei 1, Weiling Cheng1, Jiankun Dai2, Fuqing Zhou1
1The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
2MR Research, Beijing, China
Presenting Author: Zeng Wei

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Chohan H, Senkevich K, Patel RK, et al. Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Mov Disord. 2021;36(6):1420-9.doi: 10.1002/mds.28551. [doi]
2. Pagano G, Polychronis S, Wilson H, et al. Diabetes mellitus and Parkinson disease. Neurology. 2018;90(19):e1654-e62.doi: 10.1212/WNL.0000000000005475. [doi]
3. Athauda D, Evans J, Wernick A, et al. The Impact of Type 2 Diabetes in Parkinson's Disease. Mov Disord. 2022;37(8):1612-23.doi:10.1002/mds.29122. [doi]
4. Chang YH, Yen SJ, Chang YH, et al. Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. Eur J Neurol. 2021;28(2):430-7. doi:10.1111/ene.14542. [doi]
5. Borghammer P, Cumming P, Østergaard K, et al. Cerebral oxygen metabolism in patients with early Parkinson's disease. J Neurol Sci. 2012;313(1):123-8.doi: 10.1016/j.jns.2011.09.010. [doi]
6. Yan S, Lu J, Li Y, et al. Spatiotemporal patterns of brain iron-oxygen metabolism in patients with Parkinson’s disease. Eur Radiol. 2024;34(5):3074-83.doi:10.1007/s00330-023-10283-1 [doi]
7. Presta M, Zoratto F, Mulder D, et al. Hyperglycemia and cognitive impairments anticipate the onset of an overt type 2 diabetes-like phenotype in TALLYHO/JngJ mice. Psychoneuroendocrinology. 2024;167:107102. doi:10.1016/j.psyneuen.2024.107102. [doi]
8. Ketharanathan T, Hanwella R, Weerasundera R, et al. Major depressive disorder in Parkinson’s disease: a cross-sectional study from Sri Lanka. BMC Psychiatry. 2014;14(1):278. doi:10.1186/s12888-014-0278-8. [doi]
9. Barter JD, Thomas D, Ni L, et al. Parkinson’s Disease and Diabetes Mellitus: Individual and Combined Effects on Motor, Cognitive, and Psychosocial Functions. Healthcare. 2023;11(9):1316.doi: 10.3390/healthcare11091316. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/468-02-010